According to China "14th Five-Year Plan" goal, the average life of Chinese people will exceed 79 years by 2030, and early cancer screening will also be one of the important and effective ways to achieve this strategic target.
The main techniques in tumor screening include QPCR (fluorescence quantitative PCR), CLIA and Lateral Flow, etc. DxPartner has accumulated years experiences in each different application in this field. The following are some relevant products that DxPartner can develop.
Pleasecontact us if you are interested in
◆ QPCR |
|
ALK gene/ROS1 gene |
NRAS gene-mutant type |
Mutation of the BRAF gene V600E |
PIK3CA gene-mutant type |
EGFR/ALK/ROS1 gene-mutant type |
RNF180/Septin9 gene- methylation |
EGFR gene- 20 mutants |
ROS1 gene |
EML4-ALK fusion gene |
SDC2 gene-methylation |
IDH1 gene-mutant type |
Septin9 gene-methylation |
JAK2-V617F gene-mutant type |
SHOX2/RASSF1A gene-methylation |
KRAS/NRAS/PIK3CA/BRAF gene-mutant type |
TERT gene promoter-mutant type |
KRAS gene- 8 mutant types |
UGT1A1 gene-polymorphism |
MGMT gene-methylation |
Leukemia-associated fusion genes |
miR-92a |
MicroRNA |
MTHFR gene-mutant type |
|
◆ Lateral Flow |
|
Lymphotoxin α (LT-α) |
Carcinoembryonic antigen (CEA) |
Carcinoembryonic antigen (CEA) |
Golgi protein 73 (GP73) |
Fecal occult blood (FOB) |
Alpha-fetoprotein (AFP) |
Alpha-fetoprotein (AFP) |
Prostate-specific antigen (PSA) |
Chitosan 3-like protein 1 |
Carbohydrate antigen 15-3/Cancer antigen 15-3 (CA 15-3) |
Vascular endothelial growth factor (VEGF) |
Free prostate-specific antigen (Free PSA) |
◆ CLIA |
|
Golgi protein 73 (GP73) |
Abnormal prothrombin (PIVKA-II) |
